After Covid-19 vaccine, next big step may be a class of biotech antibodies


As the world awaits a Covid-19 vaccine, the next big advance in battling the pandemic could come from a class of biotech therapies widely used against cancer and other disorders - antibodies designed specifically to attack this new virus. Development of monoclonal antibodies to target the virus has been endorsed by leading scientists. Anthony Fauci, the top U.

S. infectious diseases expert, called them "almost a sure bet" against Covid-19. When a virus gets past the body's initial defenses, a more specific response.

This article is no longer available in our repository.

There could be multiple reasons for this.